Regulation of p53: TRIM24 enters the RING

Cell Cycle

Volumn 8, Issue 22, 2009, Pages 3668-3674

  Jain, Abhinav K ^a   Barton, Michelle Craig ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Cell cycle arrest; E3 ligase; Proteasome; Protein degradation; Tumor suppressor

Indexed keywords

EPITOPE; PEPTIDE; PROTEIN; PROTEIN DERIVATIVE; PROTEIN MDM2; PROTEIN P53; TIF 1ALPHA; TIF1 PROTEIN; TRIM 24 PROTEIN; TRP53 PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; BONUS GENE; CELL DEATH; DROSOPHILA; EMBRYO; EMBRYONIC STEM CELL; GENE; GENE DELETION; IN VIVO STUDY; MAMMAL; MASS SPECTROMETRY; MODEL; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN MODIFICATION; PROTEIN PURIFICATION; REGULATORY MECHANISM; REVIEW; TUMOR CELL;

MAMMALIA;

EID: 70449758781     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.22.9979     Document Type: Review

References (91)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-331
2. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-16
3. Vousden KH. p53: death star. Cell 2000; 103:691-694
4. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-431
5. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-221
6. Hu W, Feng Z, Atwal GS, Levine AJ. p53: a new player in reproduction. Cell Cycle 2008; 7:848-852 (Pubitemid 351573775)
7. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007; 7:165-168
8. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science 2006; 312:1650-1653
9. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65:177-185 (Pubitemid 40070808)
10. Feng Z, Hu W, Rajagopal G, Levine AJ. The tumor suppressor p53: cancer and aging. Cell Cycle 2008; 7:842-847 (Pubitemid 351573774)
11. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206-208
12. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2- deficient mice by deletion of p53. Nature 1995; 378:203-206
13. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21:307-315
14. Carter S, Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19:18-24.
15. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4:793-805.
16. Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 2008; 9:702-712
17. Olsson A, Manzl C, Strasser A, Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 2007; 14:1561-1575
18. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6:909-923 (Pubitemid 44862676)
19. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-412 (Pubitemid 351574202)
20. Lee KC, Crowe AJ, Barton MC. p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 1999; 19:1279-1288
21. St. Clair S, Giono L, Varmeh-Ziaie S, Resnick- Silverman L, Liu WJ, Padi A, et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 2004; 16:725-736 (Pubitemid 39586531)
22. Ho JS, Ma W, Mao DY, Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 2005; 25:7423-7431 (Pubitemid 41170106)
23. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-3257 (Pubitemid 34953189)
24. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13:2490-2501 (Pubitemid 29489641)
25. Wilkinson DS, Tsai WW, Schumacher MA, Barton MC. Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth- factor-beta-mediated transcription repression. Mol Cell Biol 2008; 28:1988-1998
26. Xie P, Tian C, An L, Nie J, Lu K, Xing G, et al. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal 2008; 20:1671-1678
27. Tsai WW, Nguyen TT, Shi Y, Barton MC. p53- targeted LSD1 functions in repression of chromatin structure and transcription in vivo. Mol Cell Biol 2008; 28:5139-5146
28. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606. (Pubitemid 27357952)
29. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999; 19:1202-1209 (Pubitemid 29046862)
30. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21:6236-6245 (Pubitemid 35415340)
31. Minsky N, Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 2004; 16:631-639 (Pubitemid 39531885)
32. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-299 (Pubitemid 27220766)
33. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-27 (Pubitemid 28037193)
34. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
35. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78:399-434.
36. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 2009; 33:275-286
37. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137:609-622
38. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13:4107-4114 (Pubitemid 23187639)
39. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS, et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12:355-366 (Pubitemid 47539309)
40. Wu X, Bayle JH, Olson D, Levine AJ. The p53- mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7:1126-1132 (Pubitemid 23979478)
41. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1:1017-1026
42. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10:501-514 (Pubitemid 44854749)
43. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000; 20:8458-8467 (Pubitemid 30805182)
44. Chan WM, Mak MC, Fung TK, Lau A, Siu WY, Poon RY. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res 2006; 4:15-25. (Pubitemid 43259886)
45. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 2005; 25:5389-5395 (Pubitemid 40853576)
46. Krummel KA, Lee CJ, Toledo F, Wahl GM. The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 2005; 102:10188-10193 (Pubitemid 41023347)
47. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505. (Pubitemid 23335075)
48. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112:779-791 (Pubitemid 36378882)
49. Sheng Y, Laister RC, Lemak A, Wu B, Tai E, Duan S, et al. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol 2008; 15:1334-1342
50. Logan IR, Gaughan L, McCracken SR, Sapountzi V, Leung HY, Robson CN. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol 2006; 26:6502-6510 (Pubitemid 44277889)
51. Hattori T, Isobe T, Abe K, Kikuchi H, Kitagawa K, Oda T, et al. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. Cancer Res 2007; 67:10789-10795 (Pubitemid 350145907)
52. Maruyama S, Miyajima N, Bohgaki M, Tsukiyama T, Shigemura M, Nonomura K, et al. Ubiquitylation of epsilon-COP by PIRH2 and regulation of the secretion of PSA. Mol Cell Biochem 2008; 307:73-82. (Pubitemid 350238649)
53. Abe K, Hattori T, Isobe T, Kitagawa K, Oda T, Uchida C, et al. Pirh2 interacts with and ubiquitylates signal recognition particle receptor beta subunit. Biomed Res 2008; 29:53-60.
54. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302:1972-1975 (Pubitemid 37523506)
55. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429:86-92. (Pubitemid 38620556)
56. Rajendra R, Malegaonkar D, Pungaliya P, Marshall H, Rasheed Z, Brownell J, et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem 2004; 279:36440-36444 (Pubitemid 39128984)
57. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARFBP1/ Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071-1083 (Pubitemid 40884397)
58. Laine A, Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2007; 26:1477-1483 (Pubitemid 46340811)
59. Boutell C, Everett RD. The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and Ubiquitinates p53. J Biol Chem 2003; 278:36596-36602 (Pubitemid 37139991)
60. Laine A, Topisirovic I, Zhai D, Reed JC, Borden KL, Ronai Z. Regulation of p53 localization and activity by Ubc13. Mol Cell Biol 2006; 26:8901-8913 (Pubitemid 44851948)
61. Andrews P, He YJ, Xiong Y. Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function. Oncogene 2006; 25:4534-4548 (Pubitemid 44175113)
62. Yang W, Rozan LM, McDonald ER, 3rd, Navaraj A, Liu JJ, Matthew EM, et al. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem 2007; 282:3273-3281 (Pubitemid 47084358)
63. Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J 2007; 26:113-122
64. Esser C, Scheffner M, Hohfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 2005; 280:27443-27448 (Pubitemid 41040787)
65. Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E, et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006; 127:775-788 (Pubitemid 44716249)
66. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001; 15:3104-3117 (Pubitemid 33115675)
67. Kruse JP, Gu W. MSL2 promotes Mdm2-independent cytoplasmic localization of p53. J Biol Chem 2009; 284:3250-3263
68. Sun L, Shi L, Li W, Yu W, Liang J, Zhang H, et al. JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Proc Natl Acad Sci USA 2009; 106:10195-10200
69. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, et al. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J 2009; 28:2100-2113
70. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci USA 2009; 106:11612-11616
71. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. EMBO J 2001; 20:2140-2151 (Pubitemid 32410584)
72. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays 2005; 27:1147-1157
73. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, et al. Human TRIM gene expression in response to interferons. PLoS One 2009; 4:4894.
74. Lan F, Collins RE, De Cegli R, Alpatov R, Horton JR, Shi X, et al. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature 2007; 448:718-722 (Pubitemid 47236862)
75. Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett 2002; 513:124-128
76. Wysocka J, Swigut T, Xiao H, Milne TA, Kwon SY, Landry J, et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 2006; 442:86-90. (Pubitemid 44064214)
77. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, et al. A possible involvement of TIF1alpha and TIF1beta in the epigenetic control of transcription by nuclear receptors. EMBO J 1996; 15:6701-6715 (Pubitemid 26413802)
78. Zeng L, Yap KL, Ivanov AV, Wang X, Mujtaba S, Plotnikova O, et al. Structural insights into human KAP1 PHD finger-bromodomain and its role in gene silencing. Nat Struct Mol Biol 2008; 15:626-633 (Pubitemid 351799130)
79. Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ, 3rd, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J 2005; 24:3279-3290
80. Wang C, Rauscher FJ, 3rd, Cress WD, Chen J. Regulation of E2F1 function by the nuclear corepressor KAP1. J Biol Chem 2007; 282:29902-29909
81. Peng H, Feldman I, Rauscher FJ, 3rd. Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: a potential mechanism for regulating the switch between coactivation and corepression. J Mol Biol 2002; 320:629-644
82. Beckstead R, Ortiz JA, Sanchez C, Prokopenko SN, Chambon P, Losson R, et al. Bonus, a Drosophila homolog of TIF1 proteins, interacts with nuclear receptors and can inhibit betaFTZ-F1-dependent transcription. Mol Cell 2001; 7:753-765 (Pubitemid 32436436)
83. McKeon F, Melino G. Fog of war: the emerging p53 family. Cell Cycle 2007; 6:229-232 (Pubitemid 46271566)
84. Lu WJ, Abrams JM. Lessons from p53 in non-mammalian models. Cell Death Differ 2006; 13:909-912
85. Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 1995; 14:2020-2033
86. Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, et al. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet 1999; 23:287-295 (Pubitemid 29526425)
87. Klugbauer S, Rabes HM. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 1999; 18:4388-4393 (Pubitemid 29392380)
88. Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, et al. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet 2007; 39:1500-1506 (Pubitemid 350191338)
89. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22:1337-1344 (Pubitemid 351717524)
90. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995; 108:1843-1848
91. Bourdon JC. p53 and its isoforms in cancer. Br J Cancer 2007; 97:277-282